Interventional News

1 week ago | interventionalnews.com | Eva Malpass

“At the publication of this public census, we’ve opened Pandora’s box and we’re going to have to make a change,” Pavan Najran (The Christie Hospital NHS Foundation Trust, Manchester, UK) said at a recent meeting, referencing a UK-wide survey looking at the use of medical devices that contain animal derivatives. Touted as the first and largest study of its kind, Najran underlined the poignancy of the results set against increasing patient autonomy, religious diversity in the UK and consent.

1 week ago | interventionalnews.com | Eva Malpass

Merit Medical Systems has announced that it has acquired Biolife Delaware in a merger transaction through which Biolife has become a wholly-owned subsidiary of Merit. Biolife manufactures patented haemostatic devices under the brand names StatSeal and WoundSeal. A press release made by Merit states that the aggregate transaction consideration, paid in cash and assumption of Biolife liabilities, was approximately US$120 million.

1 week ago | interventionalnews.com | Eva Malpass

New findings from the COVER-ALL trial suggest that software-based assessment of the minimal ablative margin during percutaneous thermal ablation significantly improves treatment precision and may reduce local tumour progression in liver cancer patients.

1 week ago | interventionalnews.com | Eva Malpass

Histotripsy is a non-thermal, non-ionising and non-invasive focused ultrasound technique which relies on cavitation for mechanical tissue breakdown at the focal point. Leading research into the novel technique, Mishal Mendiratta-Lala (University of Michigan, West Bloomfield, USA)—principal investigator for the #HOPE4LIVER trial evaluating histotripsy in liver tumours— provides a deep dive into histotripsy, discussing its application and evolution in the near future.

2 weeks ago | interventionalnews.com | Eva Malpass

Imperative Care today announced the completion of patient enrolment in its SYMPHONY-PE study, a pivotal investigational device exemption (IDE) trial evaluating the safety and efficacy of the company’s Symphony thrombectomy system for the treatment of acute pulmonary embolism (PE). Designed to expand Symphony’s current indication for use to include PE, the study was conducted at 19 leading interventional radiology, interventional cardiology and vascular surgery centres across the USA.